



1360 Willow Road ■ Suite 100 ■ Menlo Park CA 94025 ■ office: 650-833-5700 ■ fax: 650-833-6892 ■ www.virobayinc.com

FOR IMMEDIATE RELEASE

VIROBAY TO PRESENT DATA ON TWO CATHEPSIN S INHIBITOR PROGRAMS IN NEUROPATHIC PAIN AND ALZHEIMER'S DISEASE AT THE 2014 SOCIETY FOR NEUROSCIENCE ANNUAL MEETING

MENLO PARK, Calif. – November 14, 2014 – Virobay, Inc., a clinical stage pharmaceutical company with a broad platform of cathepsin protease inhibitors being developed for the treatment of neuropathic pain, autoimmune diseases and fibrosis, today announced that two moderated poster presentations will be made at the Society for Neuroscience (SFN) Annual Meeting to be held in Washington D.C. on November 15, 2014 to November 19, 2014 at the Walter E. Washington Convention Center in Washington D.C. The first poster presentation includes the results of studies investigating the use of a cathepsin S inhibitor in an experimental model of Alzheimer's Disease. These studies are the result of collaboration between Virobay and the laboratory of Dr. Mehrdad Shamloo in the Behavior and Functional Neuroscience Laboratory at Stanford University. The second poster presentation includes the results of preclinical studies in a model of chemotherapy-induced peripheral neuropathy as well as pharmacokinetic and pharmacodynamic data from early clinical studies with VBY-036, Virobay's lead cathepsin S inhibitor in development for neuropathic pain.

The presentation details are:

Sunday, November 16, Poster Session 234.23, Presentation time 1:00 PM - 5:00 PM (local time)

Authors: Bitna Yi, Andrew Evans, Leslie Holsinger, Robert Booth, Mehrdad Shamloo

Title: **Cathepsin S: A Novel Therapeutic Target for Alzheimer's Disease**

Wednesday, November 19, Poster Session 714.10, Presentation time 8:00 AM – 12:00 PM (local time)

Authors: Leslie Holsinger, Alex Marquez, Teresa Mixcoalt-Zecuatl, David Karpf, Anantha Sudhakar, Jeffrey Dener, Kyle Elrod, Robert Booth and Nigel A Calcutt

Title: **Development of a Cathepsin S Inhibitor for Neuropathic Pain: Efficacy in a Preclinical Model of Taxol-Induced Neuropathy and Phase 1 Clinical Profile**

About Virobay

Virobay is focused on the development and commercialization of novel drugs through the utilization of small molecule inhibitors of cysteine proteases, a diverse class of enzyme proteases, for a variety of conditions, including neuropathic pain, autoimmune diseases and fibrosis. Virobay's clinical pipeline currently includes product candidates in neuropathic pain, dermatology, autoimmune disease and fibrosis. For more information please visit our website: www.virobayinc.com.

Contact:

Jim Welch
Chief Financial Officer
(650) 833-5715
jim.welch@virobayinc.com